Circle Pharma Welcomes New Leaders to Enhance Drug Discovery
Circle Pharma Welcomes New Leaders to Enhance Drug Discovery
Circle Pharma, Inc., a clinical-stage biopharmaceutical company focused on developing innovative cell-permeable macrocycles, has announced significant additions to its leadership team. These appointments are crucial as the company moves forward with its promising oncology pipeline and is committed to leveraging its MXMO macrocycle platform. Recently, Marie Evangelista, Ph.D., was appointed as the Senior Vice President and Head of Cancer Biology. Additionally, Constantine Kreatsoulas, Ph.D., has been promoted to Senior Vice President and Head of Discovery Technology Sciences. This reshaping of the executive team is strategically aligned with Circle's determination to enhance its pipeline of therapies, including its leading candidate, CID-078, which is undergoing evaluation in a Phase 1 clinical trial for solid tumors.
Strengthening Drug Discovery and Scientific Leadership
According to David J. Earp, JD, Ph.D., Circle's president and CEO, these strategic hires enhance the company’s drug discovery capabilities and scientific leadership. Earp expressed enthusiasm about the trajectory of CID-078, Circle's first oral macrocyle currently in clinical trials, emphasizing the critical role that Marie and Constantine will play in leading their respective teams. Their experience will be vital as Circle Pharma continues to broaden its focus on innovative therapies.
Marie Evangelista’s Expertise in Cancer Biology
Dr. Evangelista brings a wealth of experience, with over 18 years dedicated to translational oncology and small molecule drug discovery. Her previous roles include a significant tenure at Genentech, where she led advancements in KRAS-targeting programs. With a Ph.D. in cell and molecular biology from Queen's University in Ontario, Canada, Dr. Evangelista is eager to contribute her expertise at Circle Pharma. She commented on the importance of her role during this crucial period in the company’s growth, highlighting her commitment to developing transformative therapies for patients.
Constantine Kreatsoulas and the Advancement of Macrocycle Technologies
Dr. Kreatsoulas joined Circle Pharma in 2021 and has already made notable contributions to the organization, particularly in the development of the MXMO platform. Prior to his appointment, he held leadership roles at major pharmaceutical companies like GlaxoSmithKline and Merck & Co., gaining vital experience in molecular design and machine learning. As he steps into his new role, he expresses excitement about the technological advancements in macrocycles that Circle is pursuing.
About Circle Pharma, Inc.
Circle Pharma, based in South San Francisco, is committed to advancing the discovery and development of intrinsically cell-permeable macrocycles, which can be administered through several routes, including orally. The company's proprietary MXMO™ platform employs advanced synthetic chemistry and structure-based drug design methodologies to create a new generation of macrocycle therapeutics. Circle Pharma's current focus is on cyclins—critical elements that regulate the cell cycle and have significant implications in cancer treatment. Their lead therapeutic candidate, CID-078, is in clinical trials and represents just a portion of their growing macrocycle therapeutic portfolio.
As Circle Pharma continues to innovate and expand its offerings, the leadership changes are poised to foster significant advancements in drug discovery and development efforts. This approach marks a promising step towards addressing unmet clinical needs and improving patient outcomes.
Frequently Asked Questions
What recent changes occurred in Circle Pharma's leadership?
Circle Pharma appointed Marie Evangelista as Senior Vice President and Head of Cancer Biology, and promoted Constantine Kreatsoulas to Senior Vice President and Head of Discovery Technology Sciences.
What is Circle Pharma focused on developing?
Circle Pharma is focused on developing cell-permeable macrocycles for oncology therapies, using its MXMO platform to create innovative treatments addressing unmet clinical needs.
What is CID-078?
CID-078 is Circle Pharma's leading macrocycle therapy currently undergoing a Phase 1 clinical trial targeting solid tumors.
What experience does Marie Evangelista bring to Circle Pharma?
Dr. Evangelista has over 18 years in translational oncology and drug discovery, including a significant background at Genentech, where she advanced KRAS-targeting programs.
How does Circle Pharma's MXMO platform work?
The MXMO platform combines structure-based drug design and advanced synthetic chemistry to create new macrocycle therapies aimed at challenging drug targets.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.